Beyond Your CancerIsoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.
Isoray Medical, Inc. is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers.
Based in Richland, in the shadow of the Hanford Nuclear Reservation, Isoray leveraged the expertise in the region to develop a proprietary process for manufacturing a sought after new medical isotope, Cesium 131 used in brachytherapy treatment of cancer. Brachytherapy is a technique that places radiation sources (“seeds’) as close as possible to the tumor site to destroy cancer cells.
Cesium 131 has unique characteristics that have evolved into an effective treatment for many types of cancer. Specifically, Cesium 131 is able to provide a highly targeted, fast-acting radiation treatment that is able to deliver its energy in a shorter time period than conventional external beam radiation therapy or other isotopes currently used in brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.
The initial application for Cesium 131 is for the treatment of localized prostate cancer. The fast-acting nature of the treatment allows men to quickly recover from short term side-effects from radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. A growing body of literature supports faster recovery when Cesium 131 brachytherapy is utilized.
In addition to serving as a novel, more efficient alternative for prostate brachytherapy treatment, Cesium 131 is showing great promise in other applications that previously had limited treatment alternatives, including recurrent gynecological cancers, brain tumors, sarcomas and other aggressive and recurrent tumors. Leading medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.
The fast-acting nature of the Cesium 131 isotope is well-suited to provide additional targeted radiation at the time of surgery, allowing for the treatment of residual disease while limiting the dose to surrounding healthy tissues. In many cases, the radiation “boost” can be delivered before conventional external beam radiation could even be started — while still delivering higher therapeutic doses.
In the case of brain cancer treatment, Isoray has submitted a 510(k) application for a novel delivery system developed in conjunction with the Barrow Neurological Institute (Phoenix, AZ) and is also pursuing a unique code to provide reimbursement.
Another exciting new application is for the treatment of recurrent gynecological tumors. Physicians at the University of Kentucky are using Cesium 131 to treat women with a less invasive approach, which historically has required extensive, debilitating surgical procedures. Early results are promising.
Isoray Medical is the sole producer of Cesium-131 brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is dedicated to pioneering cost-effective solutions for life beyond a patient’s cancer.
Review our SEC Filings, Codes of Conduct, & Management Teams.
We are always looking for talented people to join our team.
Join Us at the Following Events
Society of Thoracic Surgery
2018 Annual Meeting January 27-31, 2018 Fort Lauderdale, FL
American Association of Neurological Surgeons
April 30 - May 2, 2018 New Orleans, LA
American Urologic Association Annual Meeting 2018
May 18-22, 2018 San Francisco, CA
2017 saw the publication and dissemination of multiple new studies, including long-term results, and guidelines for prostate cancer treatment. Yet as the year passed by, we were surprised to discover that many clinicians remained unaware of the data and its ability to...
Will 2017 be remembered as the beginning of a brachytherapy renaissance? While much remains to be done in clinician education and patient advocacy, newly published data and patient engagement were high points for the Isoray team. A trove of new evidence demonstrates...
From the Nasdaq market site in Times Square, Isoray CEO Tom Lavoy recently spoke with Jane King, LilaMax Media CEO.
Revenue of $1.21 Million, 12% First Quarter-Over-First Quarter Increase, Gross Margin of 22% RICHLAND, Wash., Nov. 14, 2017 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
https://write2market.wistia.com/medias/avw40jp1hc?embedType=async&videoFoam=true&videoWidth=640 During Dave’s initial diagnosis for prostate cancer, his primary care physician and his urologist did not steer him toward brachytherapy. “Assuming you are not going to...
Hard Evidence: The Clinical Case for Brachytherapy Treating Intermediate- and High-Risk Prostate Cancer
Dr. Bradley Prestidge is the Medical Director of the Bon Secours Cancer Institute at DePaul Medical Center in Norfolk, Virginia. He has a deep and extensive background with brachytherapy, using the treatment to overcome prostate, breast, gynecologic and head and neck...
Cesium-131 Brachytherapy pioneer, Dr. Jonathan Feddock was recently featured by WKYT, leading the fight against recurrent gynecologic cancer. “It's estimated every six minutes in this country, a doctor diagnoses a woman with gynecologic cancer or cancer of the...
IsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer
RICHLAND, Wash., July 7, 2017 -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced...
IsoRay CEO Thomas LaVoy Talks The Future Of Cesium-131 Brachytherapy With The Wall Street Transcript
The Wall Street Transcipt recently sat with IsoRay CEO Thomas LaVoy to gain insights into the company's isotope used in brachytherapy, the patient experience, and the future of Cesium-131 in additional markets. IsoRay, Inc. (NYSEMKT: ISR) THOMAS LAVOY is Chairman of...
Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy
Study Demonstrates 100% Freedom from Local Progression Rate & 0% Rate of Radionecrosis RICHLAND, Wash., June 20, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...